Table 1.
Summary of targeted TGF-β drugs.
| Therapy | Target | Drug | Phase |
|---|---|---|---|
| Targeting TGF-β ligand | TGF-β2mRNA | AP12009 (trabedersen) | I/II/IIb |
| TGF-β1mRNA | AP11014 | Preclinical | |
| TGF-β1, β2, β3 | 1D11 | Preclinical | |
| 2G7 | Preclinical | ||
| XPA-42-068, XPA-42-681 | Preclinical | ||
| GC1008 (fresolimumab) | I/II | ||
| NIS793 | I/Ib | ||
| TGF-β1, β2 | XPA-42-089 | Preclinical | |
| αvβ6 Integrins | 264RAD | Preclinical | |
| αvβ3, αvβ5 Integrins | EMD121974 (cilengitide) | I/II/III | |
|
| |||
| Targeting TGF-β receptor | TβR I | SB431542 | Preclinical |
| SB505124 | Preclinical | ||
| SD208 | Preclinical | ||
| LY2157299 (galunisertib) | I/II | ||
| LY3200882 | I | ||
| EW-7203, EW-7195 | Preclinical | ||
| EW-7197 | I/II | ||
| TβR I/II | LY2109761 | Preclinical | |
| TβR II | CJJ300 | Preclinical | |
| Chimeric antibody-TGF-β traps | CTLA4-TβR II | Preclinical | |
| PDL1-TβR II (M7824) | I/Ib/II/III | ||
|
| |||
| Targeting the downstream mediator of TGF-β | Smads | Trx-SARA | Preclinical |
| pSmad3 | TAT-SNX9 | Preclinical | |